US · BAX
Baxter International Inc.
- Sector
- Healthcare · Medical - Instruments & Supplies
- Headquarters
- Deerfield, IL 60015
- Website
- baxter.com
Price · as of 2025-12-31
$17.21
Market cap 10.48B
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $23.79 | +38.23% |
| Intrinsic Value(DCF) | $7.88 | -54.21% |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2011 | $24.51 | $50.43 | $8.45 | $8.35 | $62.44 |
| 2012 | $29.88 | $57.83 | $7.07 | $7.27 | $35.94 |
| 2013 | $29.68 | $26.08 | $2.25 | $0.00 | $0.00 |
| 2014 | $30.47 | $37.32 | $0.92 | $2.31 | $98.27 |
| 2015 | $34.54 | $30.31 | $11.01 | $0.00 | $2.55 |
| 2016 | $44.88 | $76.28 | $3.33 | $48.53 | $91.33 |
| 2017 | $60.05 | $57.43 | $4.75 | $7.94 | $13.47 |
| 2018 | $65.31 | $61.06 | $1.78 | $12.98 | $36.83 |
| 2019 | $76.02 | $59.83 | $4.09 | $6.90 | $20.50 |
| 2020 | $70.24 | $56.01 | $3.54 | $7.64 | $23.40 |
| 2021 | $70.22 | $59.81 | $1.33 | $0.00 | $30.58 |
| 2022 | $35.49 | $24.01 | $0.00 | $0.00 | $40.17 |
| 2023 | $42.06 | $37.19 | $5.57 | $14.03 | $57.74 |
| 2024 | $36.08 | $32.52 | $1.81 | $0.00 | $0.00 |
| 2025 | $19.69 | $23.79 | $0.00 | $0.00 | $0.00 |
AI valuation
Our deep-learning model estimates Baxter International Inc.'s (BAX) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $23.79
- Current price
- $17.21
- AI upside
- +38.23%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$7.88
-54.21% upside
Graham-Dodd
—
— upside
Graham Formula
—
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| BAX | Baxter International Inc. | $17.21 | 10.48B | +38% | -54% | — | — | -10.55 | 1.65 | 0.90 | 23.68 | -27.93 | -3.19 | 30.05% | -2.74% | -8.51% | -14.62% | -1.88% | -4.18% | 1.63 | -1.06 | 2.31 | 1.31 | 10.49 | 3780.00% | 572.00% | -4222.00% | 3.20% | 0.28 | 1.97% | 3.45% | -36.40% | 39.56% | -58.89 | 56.15 | 1.61 | 2.13 |
| ATR | AptarGroup, Inc. | $143.71 | 9.43B | -31% | -59% | -82% | -45% | 23.88 | 3.52 | 2.48 | 12.63 | 366.80 | 7.03 | 29.58% | 13.53% | 10.40% | 15.28% | 11.48% | 8.11% | 0.57 | 9.69 | 1.62 | 1.04 | 1.36 | 651.00% | 542.00% | -1422.00% | 3.19% | 0.49 | 8.43% | 1.29% | 30.80% | 5.18% | 20.55 | 35.05 | 2.78 | 4.13 |
| AVTR | Avantor, Inc. | $9.05 | 6.17B | +191% | -61% | — | — | -11.27 | 1.07 | 0.91 | 68.88 | — | -2.28 | 32.65% | -3.76% | -8.09% | -9.20% | -2.61% | -4.44% | 0.71 | -1.45 | 1.78 | 1.04 | 25.82 | -17500.00% | -341.00% | -2847.00% | 8.29% | 0.45 | 5.24% | 0.00% | 0.00% | 4.92% | -38.81 | 19.30 | 1.46 | 1.37 |
| BIO | Bio-Rad Laboratories, Inc… | $278.44 | 7.52B | +7% | -54% | +41% | -13% | 10.03 | 1.02 | 2.95 | 15.99 | — | 1.14 | 52.01% | 10.47% | 29.42% | 10.84% | 3.01% | 7.62% | 0.21 | 5.52 | 5.62 | 3.90 | 2.10 | -14264.00% | 65.00% | 4072.00% | 4.91% | 1.03 | 5.46% | 0.00% | 0.00% | 3.88% | 28.14 | 20.32 | 2.95 | 3.15 |
| DVA | DaVita Inc. | $156.30 | 10.45B | -3% | -61% | — | -21% | 12.29 | -20.36 | 0.97 | 10.42 | — | -1.57 | 27.00% | 14.74% | 5.47% | -407.09% | 12.61% | 6.21% | -23.12 | 3.66 | 1.29 | 1.19 | 5.41 | -1137.00% | 646.00% | -1063.00% | 9.89% | 0.60 | 10.50% | 0.00% | 0.00% | 13.52% | 13.69 | 21.00 | 2.02 | 1.68 |
| HIMS | Hims & Hers Health, Inc. | $14.52 | 3.19B | +579% | +6,822% | -72% | +154% | 28.88 | 6.85 | 1.58 | 24.62 | — | 55.76 | 59.31% | 5.18% | 5.47% | 25.23% | 17.20% | 8.97% | 2.34 | — | 1.90 | 1.51 | 5.80 | -377.00% | 5900.00% | -6271.00% | 1.99% | 0.74 | 10.45% | 0.00% | 0.00% | 2.43% | 36.11 | 59.40 | 1.87 | 2.78 |
| MASI | Masimo Corporation | $175.35 | 9.42B | — | -60% | — | -71% | -62.06 | 13.04 | 6.16 | 31.37 | — | 16.55 | 61.90% | 20.30% | -9.92% | — | — | — | 0.72 | — | 2.49 | 1.40 | 1.17 | — | — | — | 2.10% | 0.58 | — | 0.00% | 0.00% | 3.87% | 31.51 | 49.38 | 6.40 | 8.77 |
| MDGL | Madrigal Pharmaceuticals,… | $432.00 | 9.81B | -42% | +134,896% | — | — | -33.90 | 16.22 | 10.20 | -34.57 | — | 16.42 | 94.14% | -31.31% | -30.08% | -42.49% | 761.60% | -25.05% | 0.59 | -13.45 | 4.01 | 3.60 | -0.59 | -4132.00% | 43205.00% | -5842.00% | -1.94% | -0.61 | 482.24% | 0.00% | 0.00% | 0.00% | -30.47 | -48.12 | 9.54 | 7.47 |
| QGEN | Qiagen N.V. | $49.80 | 10.26B | +6% | -52% | -77% | -45% | 23.90 | 2.69 | 4.86 | 14.93 | 5.47 | 14.69 | 61.79% | 24.90% | 20.33% | 11.57% | 10.79% | 7.09% | 0.44 | 15.65 | 3.90 | 2.93 | 1.14 | 43684.00% | 565.00% | -1049.00% | 4.46% | 1.28 | 10.85% | 0.53% | 12.80% | 1.82% | 20.58 | 23.63 | 5.12 | 3.92 |
| RGEN | Repligen Corporation | $128.73 | 7.25B | -26% | -60% | -83% | -84% | 143.73 | 3.34 | 9.52 | 42.30 | — | 11.60 | 47.09% | 8.07% | 6.62% | 2.40% | 2.38% | 1.69% | 0.33 | 2.57 | 8.37 | 6.82 | 0.75 | -28696.00% | 1636.00% | -3410.00% | 1.34% | 0.86 | 4.78% | 0.00% | 0.00% | 0.00% | 116.65 | 74.02 | 9.41 | 5.94 |
| RNA | Avidity Biosciences, Inc. | $14.75 | 2.28B | +47% | -35% | — | — | -3.00 | 1.22 | 109.48 | -0.66 | -4.17 | 1.22 | 77.87% | -3977.30% | -3650.39% | -43.98% | -9010.06% | -38.88% | 0.06 | — | 9.20 | 8.75 | 0.42 | 7197.00% | 7211.00% | 11555.00% | -32.33% | -3.33 | -8017.39% | 0.00% | 0.00% | 3.65% | -0.60 | -0.68 | 24.04 | 3.18 |
About Baxter International Inc.
Baxter International Inc., through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company offers peritoneal dialysis and hemodialysis, and additional dialysis therapies and services; intravenous therapies, infusion pumps, administration sets, and drug reconstitution devices; remixed and oncology drug platforms, inhaled anesthesia and critical care products and pharmacy compounding services; parenteral nutrition therapies and related products; biological products and medical devices used in surgical procedures for hemostasis, tissue sealing and adhesion prevention; and continuous renal replacement therapies and other organ support therapies focused in the intensive care unit. It also provides connected care solutions, including devices, software, communications, and integration technologies; integrated patient monitoring and diagnostic technologies to help diagnose, treat, and manage a various illness and diseases, including respiratory therapy, cardiology, vision screening, and physical assessment; surgical video technologies, tables, lights, pendants, precision positioning devices and other accessories. In addition, the company offers contracted services to various pharmaceutical and biopharmaceutical companies. Its products are used in hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors' offices, and patients at home under physician supervision. The company sells its products through direct sales force, as well as through independent distributors, drug wholesalers, and specialty pharmacy or other alternate site providers in approximately 100 countries. It has an agreement with Celerity Pharmaceutical, LLC to develop acute care generic injectable premix and oncolytic molecules. Baxter International Inc. was incorporated in 1931 and is headquartered in Deerfield, Illinois.
- CEO
- Andrew Hider
- Employees
- 38K
- Beta
- 0.58
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($7.88 ÷ $17.21) − 1 = -54.21% (DCF, example).